BRAF V600 MUTATION
Clinical trials for BRAF V600 MUTATION explained in plain language.
Never miss a new study
Get alerted when new BRAF V600 MUTATION trials appear
Sign up with your email to follow new studies for BRAF V600 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Matched conditions: BRAF V600 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can we stop these cancer drugs without the tumor coming back?
Disease control Recruiting nowThis study looks at whether patients with a certain type of slow-growing brain tumor (low-grade glioma with a BRAF V600 mutation) can safely stop or reduce their dose of two targeted drugs, dabrafenib and trametinib, after 12-24 months of treatment. About 96 participants will eit…
Matched conditions: BRAF V600 MUTATION
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can tailored drugs after surgery keep melanoma from coming back?
Disease control Recruiting nowThis early-phase trial tests whether giving different drug combinations after surgery, based on how well the tumor responded to initial treatment, can reduce the risk of melanoma returning. About 50 adults with stage III or IV BRAF-mutant melanoma will receive encorafenib, binime…
Matched conditions: BRAF V600 MUTATION
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC